feed,title,long_url,short_url
Benzinga,"ESR1 Mutated Metastatic Breast Cancer Market Anticipated to Propel with an Escalated CAGR of 4.48% for the Study Period 2018-30, Investigates DelveInsight",https://benzinga.com/pressreleases/21/10/n23490990/esr1-mutated-metastatic-breast-cancer-market-anticipated-to-propel-with-an-escalated-cagr-of-4-48-,
